The Unmet Need in BCG-Unresponsive NMIBC

Bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) represents one of the most clinically challenging management problems in urologic oncology—a disease state where the standard-of-care recommendation for radical cystectomy is frequently at odds with patient fitness, patient preference, and the growing availability of bladder-sparing alternatives. In the first segment of this series, Mark D. Tyson II, MD, MPH, a professor of urology at Mayo Clinic in Phoenix, Arizona, surveys the current treatment landscape and identifies the unmet needs that continue to drive development in this space, even as a widening array of intravesical and systemic options reaches clinical practice.

Tyson notes that although radical cystectomy remains an oncologically effective operation, its perioperative risk—including a 1% to 2% mortality rate at experienced centers—combined with the functional and quality-of-life implications of urinary diversion make it a substantial undertaking, particularly for patients who are medically complex or elderly. Many patients in this setting strongly prefer bladder preservation when it can be offered without compromising the window of curative intent, and Tyson emphasizes that this preference has only grown as more approved agents have entered the field. He frames the shared decision-making conversation around bladder-sparing therapy as nuanced: It requires balancing realistic expectations for durability against the imperative not to delay cystectomy in patients with disease that has progressed or that poses meaningful risk of upstaging.

When evaluating a new bladder-sparing therapy, Tyson describes a hierarchy of end points that shapes his clinical interpretation. He begins with the trial's primary end point—generally complete response rate—but weights durability equally or more heavily, with particular attention to response rates at 12 and 24 months. He also examines progression rates, cystectomy-free survival, and tolerability, noting that preserving a patient's bladder while exposing them to an unacceptable symptom burden is not a satisfactory clinical outcome. Although cystectomy-free survival is a meaningful patient-centered end point, he acknowledges that it can be influenced by clinician enthusiasm for surgery and patient attitudes toward cystectomy in small, nonrandomized trials—a caveat he keeps in mind when interpreting data across the growing portfolio of agents in this space.